Acticor Biotech
Clinical-stage biopharma developing glenzocimab, an antithrombotic antibody fragment for acute ischemic stroke patients
Highlights
- Hiring1 open role
- New on EvolcAdded 2026-11-02
About Acticor Biotech
Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, a humanized antibody fragment (Fab) that targets the platelet glycoprotein GPVI. The drug is being developed as an add-on treatment for cardiovascular emergencies and acute thrombotic diseases, with a primary focus on acute ischemic stroke.
The company is a spin-off from INSERM, the French National Institute of Health and Medical Research, and its business is based on developing a single drug candidate.
Acticor Biotech is headquartered in Paris, France. Glenzocimab received Priority Medicines (PRIME) status from the European Medicines Agency in July 2022 for the treatment of stroke. Its ACTISAVE phase 2/3 trial randomized 436 patients, and the company is a partner in the RHU BOOSTER consortium running the GREEN study.
Product: Glenzocimab (ACT017), a humanized Fab antibody fragment against platelet GPVI, in clinical development for acute ischemic stroke.
Jobs at Acticor Biotech (1)
Acticor Biotech is hiring for one role in legal.
Leadership
- Martine Jandrot-Perrus · Scientific FounderSource: company website
- Philippe Billiald · Scientific FounderSource: company website
- Gilles Avenard · Chief Executive OfficerSource: company website
- François Guillet · Chief Financial OfficerSource: company website
More biotech & pharma companies
Ademtech
Magnetic particles and molecular diagnostic kits for IVD, life sciences and forensic laboratoriesNew on EvolcAdocia
Develops clinical-stage treatments for diabetes and obesity for patients with metabolic diseasesNew on EvolcAdragos Pharma
Contract development and manufacturing for pharma and biotech clients in Europe, Japan and North AmericaAdvesya
Clinical-stage biotech developing IL-1RAP-targeted CAR T-cell and ADC treatments for cancer and autoimmune diseasesNew on EvolcAelis Farma
Develops CB1-targeted drug candidates for people with cannabis-related disorders and cognitive deficitsNew on EvolcAenitis Technologies
Acoustic levitation cell-handling devices and single-use consumables for cell and gene therapy bioprocessingNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WebflowMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Hosting
- LiteSpeedHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.